http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210130570-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate | 2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210130570-A |
| titleOfInvention | Pharmaceutical composition for preventing or treating chemotherapy-induced peripheral neuropathy comprising the antibody of interleukin 23 |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating peripheral neuropathy induced by a drug comprising an antibody specifically binding to IL-23p19 of interleukin 23. In the present invention, it was newly clarified that an antibody that specifically binds to IL-23p19 of interleukin 23 blocks the interaction with interleukin receptor to suppress pain. In related fields for the purpose of prevention and treatment, it may be used in various ways as new therapeutic agents and anticancer adjuvants. |
| priorityDate | 2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 266.